Bristi Basu, MD, honorary consultant medical oncologist, University of Cambridge, discusses second-line therapy for hepatocellular carcinoma (HCC).

Researchers had not seen efficacy with any agents in the second-line setting until the RESOURCE trial. This was a phase III study with 2:1 randomization of regorafenib (Stivarga) versus sorafenib (Nexavar). These are 2 very similar tyrosine kinase inhibitors with slightly different mechanisms of action. This slight distinction allows regorafenib to have activity against VEGF-2 and FGF1. Data showed a survival advantage for regorafenib compared with placebo, 10.6 months versus 7.8 months, respectively. Response rates were modest, about 11%.

Basu adds that this was a patient population with a generally good prognosis. They were able to tolerate sorafenib at a dose of 400 mg/day for 20 days, but progressed on the treatment. There were similar adverse events with regorafenib as are seen in patients treated with sorafenib.

Videos

Bristi Basu, MD, honorary consultant medical oncologist, University of Cambridge, discussed second-line therapy for patients with hepatocellular carcinoma.

Bristi Basu, MD

Articles

Dr. Basu on Second-Line Therapy in HCC